000			03721nab a22003497a 4500
999			_c7343 _d7343
005			20250625151559.0
008			211108s2021 ||||| |||| 00| 0 eng d
040			_aAFVC
100			_aPeitzmeier, Sarah M. _910375
245			_aThe transgender-specific intimate partner violence scale for research and practice : _bvalidation in a sample of transgender women _cSarah M. Peitzmeier, Andrea L. Wirtz, Elizabeth Humes, Jaclyn M. W. Hughto, Erin Cooney, Sari L. Reisner and American Cohort To Study HIV Acquisition Among Transgender Women (LITE)
260			_bElsevier, _c2021
500			_aSocial Science & Medicine, 2021, 291: 114495
520			_aStudy/research objective: To develop and validate a brief intimate partner violence (IPV) scale that screens for controlling behaviors and psychological abuse tactics directed toward transgender individuals. Rationale: Transgender individuals are at elevated risk of physical and sexual IPV compared to cisgender individuals. IPV often takes on unique dimensions against transgender individuals, such as when an abusive partner threatens to “out” the transgender person, or use other tactics that weaponize transphobia within the relationship. Standard IPV screeners do not assess this type of transgender-specific IPV (T-IPV). Methods: Between March 2018 and October 2019, a T-IPV scale was tested in two samples (in-person and online) of transfeminine adults (i.e. assigned a male sex at birth and identify with femininity) from the eastern and southern U.S. Exploratory factor analysis (EFA) was conducted with the in-person sample (N = 661) to assess construct validity. Confirmatory factor analysis (CFA) was then used in an independent online sample (N = 481). Using the combined sample (N = 1137), convergent validity was assessed using correlations with other forms of victimization. Multivariable regression models were fit to estimate the relationship between T-IPV and health outcomes. Results: Factor analyses yielded an 8-item unidimensional scale with moderate to good fit. Nearly half the sample (48.7%) experienced at least one scale item. Internal consistency reliability was strong (KR-20 = 0.827). Significant correlations with other forms of victimization indicated convergent validity. Lifetime T-IPV was significantly associated with psychological distress (adjusted prevalence ratio [aPR] = 1.32, 95% CI = 1.13, 1.53), PTSD (aPR = 1.50, 95%CI = 1.31, 1.72), alcohol abuse (aPR = 1.21, 95%CI = 1.01, 1.44), and drug use disorder (aPR = 1.30, 95%CI = 1.06, 2.59). Conclusions: This T-IPV scale is a reliable and unidimensional measure with strong construct validity. T-IPV is independently associated with mental health burden and substance use. Service providers working with transgender clients should screen for T-IPV to avoid missing cases of IPV, and refer to violence response services. (Authors' abstract). Record #7343
650			_aDOMESTIC VIOLENCE _9203
650			_aINTIMATE PARTNER VIOLENCE _9431
650		0	_aLGBTQIA+ _93453
650			_aSCREENING _93081
650			_aTRANSGENDER _93315
650			_aWOMEN _9645
651			_aINTERNATIONAL _93624
651		4	_aUNITED STATES _92646
700			_aWirtz, Andrea L, _910377
700			_aHumes, Elizabeth _910378
700			_aHughto, Jaclyn M. W. _910379
700			_aCooney, Erin _910380
700			_aReisner, Sari L. _910381
710			_aAmerican Cohort To Study HIV Acquisition Among Transgender Women (LITE) _910382
773	0		_tSocial Science & Medicine, 2021, 291: 114495
830			_aSocial Science & Medicine _95308
856			_uhttps://doi.org/10.1016/j.socscimed.2021.114495 _zDOI: 10.1016/j.socscimed.2021.114495
942			_2ddc _cARTICLE